Proteros Biostructures Expands Successful Protein Crystallography Collaboration With OSI Pharmaceuticals
News Mar 11, 2008
Proteros biostructures GmbH has announced the expansion of its collaboration with OSI Pharmaceuticals, Inc. in the field of protein crystallography. Following the successful delivery of valuable high resolution protein-ligand-structures on multiple kinase targets under Proteros’ Gallery Structure mode with compounds supplied by OSI, Proteros will now provide also Gene-to-Structure services to OSI.
This Gene-to-Structure agreement marks the fifth project under the master service agreement signed in October 2007. Under it Proteros will utilize its capabilities in construct design, protein expression and purification as well as protein structure determination to deliver a de novo protein structure and several protein-ligand-structures on a challenging kinase target to OSI.
Dr. Torsten Neuefeind, Proteros’ Chief Executive Officer, commented: “The successes so far demonstrate that the combination of Proteros’ industrial approach, unique technologies and expertise can quickly generate valuable structural data to meet the highest quality standards required by OSI. We look forward to continuing to demonstrate the value of this collaboration and contributing to accelerating drug discovery programmes at OSI.”
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE